First generation design, synthesis, and evaluation of azepine-based cryptophycin analogues

Organic Letters

Volumn 3, Issue 25, 2001, Pages 4063-4066

  Smith III, Amos B ^a   Cho, Young Shin ^a   Zawacki, Lisa E ^a   Hirschmann, Ralph ^a   Pettit, George R ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b ARIZONA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AZEPINE DERIVATIVE; CRYPTOPHYCIN; CYCLOPEPTIDE;

ANIMAL; ARTICLE; CELL CULTURE; CHEMICAL STRUCTURE; CHEMISTRY; CYANOBACTERIUM; DRUG DESIGN; DRUG SCREENING; HUMAN; SYNTHESIS; X RAY CRYSTALLOGRAPHY;

ANIMAL; ANTINEOPLASTIC AGENTS; AZEPINES; CRYSTALLOGRAPHY, X-RAY; CYANOBACTERIA; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; HUMAN; MOLECULAR STRUCTURE; PEPTIDES, CYCLIC; SUPPORT, U.S. GOV'T, P.H.S.; TUMOR CELLS, CULTURED;

EID: 0035856897     PISSN: 15237060     EISSN: None     Source Type: Journal    
DOI: 10.1021/ol016799g     Document Type: Article

References (38)

1. (a) Schwartz, R. E.; Hirris, C. F.; Sesin, D. F.; Flor, J. E.; Chartrain, M.; Fromtling, R. E.; Harris, G. H.; Salvatore, M. J.; Liesch, J. M.; Yudin, K. J. Ind. Microbiol. 1990, 5, 113.
2. (b) Hirsch, C. F.; Liesch, J. M.; Salvatore, M. J.; Schwartz, R. E.; Sesin, D. F. U.S. Patent 4,946, 835, August 7, 1990.
3. (a) Golakoti, T.; Ogino, J.; Heltzel, C. E.; Le Husebo, T.; Jensen, C. M.; Larsen, L. K.; Patterson, G. M. L.; Moore, R. E.; Mooberry, S. L.; Corbett, T. H.; Valeriote, F. A. J. Am. Soc. Chem. 1995, 117, 12030 and references therein.
4. (b) Corbett, T. H.; Valeriote, F. A.; Demchik, L.; Lowichik, N.; Polin, L.; Panchapor, C.; Pugh, S.; White, K.; Kushner, J.; Rake, J.; Wentland, M.; Golakoti, T.; Hetzel, C.; Ogino, J.; Patterson, G.; Moore, R. Invest. New Drugs 1997, 15, 207.
5. (c) Panda, D.; Himes, R. H.; Moore, R. E.; Wilson, L.; Jordan, M. A. Biochemistry 1997, 36, 12948.
6. (a) Mooberry, S. L.; Busquets, L.; Tien, G. Int. J. Cancer 1997, 73, 440 and references therein.
7. (b) Bai, R.; Durso, N. A.; Sackett, D. L.; Hamel, E. Biochemistry 1999, 38, 14302.
8. (a) Kobayashi, M.; Kurosu, M.; Wang, W.; Kitagawa, I. Chem. Pharm. Bull. 1994, 42, 2394.
9. (b) Barrow, R. A.; Hemscheidt, T.; Liang, J.; Paik, S.; Moore, R. E.; Tius, M. A. J. Am. Chem. Soc. 1995, 117, 2479.
10. Eggen, M.; Nair, S. K.; Georg, G. I. Org. Lett. 2001, 3, 1813 and references therein.
11. (a) Norman, B. H.; Hemscheidt, T.; Schultz, R. M.; Andis, S. L. J. Org. Chem. 1998, 63, 5288.
12. (b) Liang, J.; Moher, E. D.; Moore, R. E.; Hoard, D. W. J. Org. Chem. 2000, 65, 3143.
13. (a) Wagner, M. M.; Paul, D. C.; Shih, C.; Jordan, M. A.; Wilson, L.; Williams, D. C. Cancer Chemother. Pharmacol. 1999, 43, 115 and references therein.
14. (b) Panda, D.; Ananthnarayan, V.; Larson, G.; Shih, C.; Jordan, M. A.; Wilson, L. Biochemistry 2000, 39, 14121
15. (c) Kessel, D.; Luo, Y. Cancer Lett. 2000, 151, 25.
16. Hirschmann, R.; Ducry, L.; Smith, A. B., III J. Org. Chem. 2000, 65, 8307 and references therein.
17. Specific details of these studies are outlined in Supporting Information.
18. Campbell, A. L.; Pilipauskas, D. R.; Khanna, I. K.; Rhodes, R. A. Tetrahedron Lett. 1987, 28, 2331.
19. (a) Grubhs, R. H.; Miller, S. J.; Fu, G. C. Acc. Chem. Res. 1995, 28, 446.
20. (b) Miller, S. J.; Blackwell, H. E.; Grubbs, R. H. J. Am. Chem. Soc. 1996, 118, 9606.
21. (a) Martínez, L. E.; Leighton, J. L.; Carsten, D. H.; Jacobsen, E. N. J. Am. Chem. Soc. 1995, 117, 5897.
22. (b) Leighton, J. L.; Jacobsen, E. N. J. Org. Chem. 1996, 61, 389.
23. (c) Schaus, S. E.; Larrow, J. F.; Jacobsen, E. N. J. Org. Chem. 1997, 62, 4197.
24. (d) To the best of our knowledge, epoxide opening with alcohol in the presence of the Jacobsen catalyst (S,S)-9 has not been reported.
25. (a) Borch, R. F.; Bernstein, M. D.; Durst, H. D. J. Am. Chem. Soc. 1971, 93, 2897.
26. (b) Borch, R. F.; Hassid, A. I. J. Org. Chem. 1972, 37, 1673.
27. Charkraborty,T. K.; Thippeswamy, D.; Suresh, V. R.; Jayaprakash, S. Chem. Lett. 1997, 563.
28. Dess, D. B.; Martin, J. C. J. Am. Chem. Soc. 1991, 113, 7277.
29. for a review, see: Maryanoff, B. E.; Reitz, A. B. Chem Rev. 1989, 89, 863.
30. Kim, G.; Chu-Moyer, M. Y.; Danishefsky, S. J.; Schulte, G. K. J. Am. Chem. Soc. 1993, 115, 30.
31. Chen, Y. L.; Nielsen, J.; Hedberg, K.; Dunaiskis, A.; Jones, S.; Russo, L.; Johnson, J.; Ives, J.; Liston, D. J. Med. Chem. 1992, 35, 1429.
32. 2 prior to epoxidation [Ferrer, M.; Sánchez-Baeza, F.; Messeguer, A.; Diez, A.; Rubiralta, M. J. Chem. Soc., Chem. Commun. 1995, 293]. After purification of the mixture of epoxides (1:1) by preperative TLC, only the α-epoxide was recovered, in 20% yield.
33. Preparation of (-)-17 is outlined in Supporting Information.
34. The major side product (60%) was an elimination product of (-)-17; the recovered starting material 16 proved to be a racemic mixture.
35. Horning, E. C. Organic Syntheses: Wiley: New York, 1943; Collect. Vol. III, p 267.
36. Majer, P.; Randad, R. S. J. Org. Chem. 1994, 59, 1937.
37. Kolb, H. C.; Sharpless, K. B. Tetrahedron 1992, 48, 10515.
38. 50 value of 0.037 nM (0.000025 μg/mL) against the MCF-7 mammary carcinoma (see ref 7a).